Surging domestic incidence of oncology, autoimmune, and metabolic disorders alongside a rapidly aging population, expanding National Medical Products Administration (NMPA) regulatory reforms and National Reimbursement Drug List (NRDL) inclusion, and continuous biotechnology innovations in antibody-drug conjugates (ADCs), bispecific antibodies, and cell therapies are driving rapid growth across...